MedPath

De toegevoegde waarde van magnetic resonance imaging in detectie van prostaatkanker.

Conditions
prostate cancer detection, diagnose prostaatkanker
Registration Number
NL-OMON21521
Lead Sponsor
Radboud University Medical CentreDepartment of Radiology
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
80
Inclusion Criteria

1. PSA¡Ý4.0 ng/ml;

2. One or more previous negative TRUS guided prostate biopsies;

Exclusion Criteria

1. Patients with known contradictions to MRI;

2. Patients with known contra-indications to Gadolinium based contrast agents;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Detection rates of MRGB compared to a second or later TRUSGB examination. Timepoint:8 weeks.
Secondary Outcome Measures
NameTimeMethod
1. Detection rate of MRUSFGB. Timepoint: 8 weeks;<br /><br>2. Percentage of patients upgraded(with an increase of one point in Gleason score on MRGB and MRUSFGB compared tot TRUSGB) by MRGB and MRUSFGB Gleason score respectively compared to TRUSGB Gleason score. Timepoint: 8 weeks.<br>
© Copyright 2025. All Rights Reserved by MedPath